<html xmlns="http://www.w3.org/1999/xhtml"><head>
        <meta http-equiv="Content-Type" content="text/html; charset=utf-8">
        <meta name="viewport" content="width=device-width, height=device-height, initial-scale=0.5, minimum-scale=0.5, user-scalable=yes, maximum-scale=2.0, target-densitydpi=device-dpi" />
				<meta name="robots" content="all"/>
        <meta name="description" content="description">
        <meta name="keywords" content="">
        <title>Page 366 - MIMS April 2020 E4</title>
<style type="text/css">
<!--
body {
	margin-left: 0px;
	margin-top: 0px;
	margin-right: 0px;
	margin-bottom: 0px;
}
  
#container {margin:50px auto;padding:0px;width:910px;}
#left-button{ width:90px; height:100%;float:left }
#middle{ width:730px; margin:0px; float: left;}
#right-button{ width:90px; float:left;}
html, body, div, ul, li, dl, dt, dd, h1, h2, h3, h4, h5, h6, form, input, dd,select, button, textarea, iframe, table, th, td { margin: 0; padding: 0; }
img { border: 0 none; displayblock}
span,ul,li,image{ padding:0px; margin:0px; list-style:none;}
#top-title{ width:714px; margin-bottom:10px; float:left; padding:0px 8px}
#top-title2{ width:320px;  float:right;}
#content{ width: 730px; float:left;float:left;word-wrap: break-word;}
#content-top{ width:730px; background-image:url(images/top_bg.jpg); height:56px; background-repeat:no-repeat; float:left;}
#content-top1{ width:70%; padding:16px 0px 0px 30px; font-family:Arial, Helvetica, sans-serif; font-size:24px; color:#636363;float:left;}
#content-top2{ width:60px; float:right; padding:25px 30px 0px 0px;font-family:Arial, Helvetica, sans-serif; font-size:11px; color:#2f2f2f; font-weight:bold; text-align:right}
#content-middle{ width:730px; background-image:url(images/middle_bg.jpg); background-repeat:repeat-y;float:left;}
#content-middle1{ width:475px; padding:25px 0px 25px 35px; font-family:Arial, Helvetica, sans-serif; font-size:12px; color:#636363; line-height:150%;float:left;}
#content-middle2{  padding:7px; float:right; margin:25px 35px 0px 0px; border:solid 1px #c8c8c9; background-color:#FFF; text-align:center}
#content-bottom{ width:730px; background-image:url(images/bottom_bg.jpg); background-repeat:no-repeat; height:58px;float:left;}
#content-bottom2{ width:110px; height:42px; margin:0px auto; padding-top:4px;}
#input{ width:58px; height:20px; background-color:#FFF; border:solid 1px #dfdfe0; color:#636363; text-align:center; font-size:11px;}
.font1{ font-family:Arial, Helvetica, sans-serif; font-size:10px; color:#2f2f2f;}
.font1 a:link{
	text-decoration: none;
    color:#2f2f2f;

}
.font1 a:visited{
	text-decoration: none;
    color:#2f2f2f;
	
}
.font1 a:hover{
	color: #2f2f2f;
	text-decoration: underline;

}



.text-container {
padding: 20px;
color: #333;
margin-top: 24px;
line-height: 22px;
border-top-left-radius: 3px;
border-top-right-radius: 3px;
}

.use-as-video {
float: right;
padding-left: 20px;
}
.cc-float-fix:before, .cc-float-fix:after {
content: "";
line-height: 0;
height: 0;
width: 0;
display: block;
visibility: hidden;
}
.use-as-video-img {
cursor: pointer;
position: relative;
width: 320px;
height: 180px;
}
.use-as-video-title {
font-size: 15px;
font-weight: bold;
color: #000000;
padding-bottom: 5px;
}
-->
</style>
<script type="text/javascript">
<!--
function MM_preloadImages() { //v3.0
  var d=document; if(d.images){ if(!d.MM_p) d.MM_p=new Array();
    var i,j=d.MM_p.length,a=MM_preloadImages.arguments; for(i=0; i<a.length; i++)
    if (a[i].indexOf("#")!=0){ d.MM_p[j]=new Image; d.MM_p[j++].src=a[i];}}
}

function MM_swapImgRestore() { //v3.0
  var i,x,a=document.MM_sr; for(i=0;a&&i<a.length&&(x=a[i])&&x.oSrc;i++) x.src=x.oSrc;
}

function MM_findObj(n, d) { //v4.01
  var p,i,x;  if(!d) d=document; if((p=n.indexOf("?"))>0&&parent.frames.length) {
    d=parent.frames[n.substring(p+1)].document; n=n.substring(0,p);}
  if(!(x=d[n])&&d.all) x=d.all[n]; for (i=0;!x&&i<d.forms.length;i++) x=d.forms[i][n];
  for(i=0;!x&&d.layers&&i<d.layers.length;i++) x=MM_findObj(n,d.layers[i].document);
  if(!x && d.getElementById) x=d.getElementById(n); return x;
}

function MM_swapImage() { //v3.0
  var i,j=0,x,a=MM_swapImage.arguments; document.MM_sr=new Array; for(i=0;i<(a.length-2);i+=3)
   if ((x=MM_findObj(a[i]))!=null){document.MM_sr[j++]=x; if(!x.oSrc) x.oSrc=x.src; x.src=a[i+2];}
}
//-->
</script>
</head>

<body onload="MM_preloadImages('images/next2.png','images/previous2.png')">
<div id="container">
<div id="left-button">
  <p>&nbsp;</p>
  <p>&nbsp;</p>
  <p>&nbsp;</p>
  <p>&nbsp;</p>
  <p>&nbsp;</p>
  <p><a href="page365.html"><img src="images/previous_big.png" width="90" height="80" /></a></p>
</div>
<div id="middle">
  <div id="top-title"><span class="font1">Basic HTML Version</span>
    <div id="top-title2">
      <table width="100%" border="0" align="right" cellpadding="0" cellspacing="0">
        <tr>
        	<td width="66%"> </td>
          <td width="35%" style="display:none" align="right"><img src="images/content.png" width="19" height="16" /></td>
          <td width="31%" style="display:none" class="font1"><a href="">Table of Contents</a></td>
          <td width="6%"><img src="images/view.png" width="19" height="16" /></td>
          <td width="28%" class="font1"><a href="../../MIMS April 2020 E4.html#p=366">View Full Version</a></td>
        </tr>
      </table>
    </div>
  </div>
  <div id="content">
     <div id="content-top">
        <div id="content-top1">Page 366 - MIMS April 2020 E4</div>
        <div id="content-top2">P. 366</div>
     </div>
     <div id="content-middle">
     	
     	  <div class="text-container">
    <div class="use-as-video cc-float-fix">
      <a style="text-decoration: none;" href="../../MIMS April 2020 E4.html#p=366"><img src="../thumb/366.jpg" /></a>
    </div>

    <p class="use-as-video-title"></p>
    <pre style="white-space:pre-line"><code>Immunological - 24.1                                                           2020-04 / 329
       Side effects: Anaphylax., malign.partic.of skin, incr. infect.suscept.,   latex sens., discont.ther. immed. & appropr.treatm.if anaphylact./other   Aft.fail.of std.ther.: Adults: Init.200 mg dly.as sngl. dos.in even. Incr.
       ren./hepat.dysfunct., trem., headache, paraesthes., encephalopathy   ser.allerg. react.occur, safety & effic.in paed.pts. not est., elderly, no   by 100 mg at wkly interv. to max.400 mg dly.accord.to tol.& toxic.
       signs, convuls., confus., disorientat., decr.responsiven., agitat., in-  studies in ren./ hepat. impairm., rare heredit.fruct.intol.probl., women   ENL: Adults: Init.400 mg dly.as sngl.night time dos. Contin.x1-4
       somn., vis.disturbs., coma, paresis, cerebell. atax., motor polyneurop-  of child-bear.potent.not to become pregn.dur.ther., sev. ill./ immuno-  wks.depend.on clinic.respons. then decr.by upto 100 mg every 2
       athy, benign IC hypertens., GI disturbs., pancreatit., pept.ulc., gastrit.,   compromis.pts., ser.bact infects./ TB & invas.fung.infects.with fatalit.,   wks.to est. maint.dos of 50 mg dly. Tot.treatm.durat.depends on
       hyperglycaem./-uricaem./-kalaem./-lipidaem., hypomagnesaem.,   pt.to be advis./ avoid expos.to potent.infect.risk fact., lymphoma, ALT   indiv.with recom.minim.tot.durat.x7 wks. Pts. weigh. less than
       musc.cramps/ weakn., myalg., myopathy, anaem., thrombocyto-  elev., auto-antibody format.& rarely lupus-like syndr.developm., ser.  50 kg: Init.dos.300 mg dly.
       paen., leucopaen., micro-angiopath. haemolyt.anaem., haemolyt.  hypersens. react. incl.anaphylact.reacts./sarcoidos., hepatit.B virus   Contra-indications: Pregn., poss.pregn.dur.ther., women of child
       uraem.syndr., hypertrichos., allerg.skin reacts., prurit., acne., fatig.,   reactiv.in chron.carriers, worsen./new onset CHF  bear.potent.unless alter.ther. inappropr., breast feed., women of
       oed., weight incr., flush., hypertherm., menstr. disturbs., gynae-  See also MDR page 424.  child bear. potent.not using/not able to use adeq.contracept. meas.
       comast., hypertens., gingiv. hyperplas, incr.ser.bilirub./liv.enzym.  as outline in program., sex.mature males not able/will.to comply
       Warnings and special precautions: Benef.vs. risk ratio in pre-  SIMULECT, Novartis [P/S]  with contracept.meas.outline in program., pts.for whatever reas.
       exist.ren./hepat.dis., monit. paramet. that assess ren.& hepat.funct.  Basiliximab  unable to understand/comply with program.instruct., not recomm.
       closely., use by exper.physic.only, reg.follow-up, monit. caref. for   Indications: Ac.organ reject.prophylax.in de novo ren. transplant in   for use in childr.und.12 yrs.as safety & effic.not est., S&S of periph.
       anaphylax., allerg.predisposit., pts.to be cont. monit.for at least first   adult & paed.pts.with concom. cyclosporine for micr-emuls. & corti-  neuropathy unless benef.outweighs risks.
       30 mins.aft.infus.start & freq.interv.theraft., incr.risk of lymphoma/   coster./in tripl. maint. immunosuppress. regimen cont.ciclospor. for mi-  Side effects: Sev.life threaten.human birth defects, drowsin., som-
       malign. esp.of skin, discont.if pre-malign./malign. detect., poss.  cr-emuls./ corticoster.& either azathioprine/ mycophenolate mofetil.  nol., sedat., constipat., asthen., periph.neuropathy/aggrav.with poss.
       lymphoproliferat.disords.with multipl. immunosuppress. treatm.  (S4) INJ. 32/34/0752. 20 mg/vial  irrevers.damage, orthostat.hypotens., neutropen., sev.skin reacts.
       regim., pre-emptive/ therapeut. strategy in longt.ther.for oppor-  862479-0002: Sngl.vials, R16 695,28  incl.Stev.John.syndr.& tox.epiderm. necrolys., leukopen., incr.appe-
       tunist. infects., hyperuricaem./kalaem., monit.ren.funct.at least   Dosage: Admin.as IV infus. over 20-30 mins.or as bolus inj.  tite, mood/libido changes, CNS effs.incl.seiz., card.arrythm., DVT,
                                     Adults: 20 mg 2 hrs.pre-op. then 20 mg 4 days aft. transplant. Tot.
       2x bef.commenc.ther.& then 2-wkly.dur.1st 3 mnths. of treatm.&   brady-& tachycard., thrombo-embol.reacts., orthostat. hypotens.,
       mnthly thereaft.if creatin. remains stable & when dos.incr./concom.  dos.40 mg. Withold 2nd dos.in case of post-op complicat. Childr.1-17   GI disturbs., rash, urticar., prurit., dry skin, fac.oed., photosens., bull.
                                     yrs: Bm &lt; 35 kg: Recomm.tot.dos.20 mg in 2 dos.of 10 mg each. Bm
       NSAID init. & if dos.incr., monit.ren./liv.funct.with concom. NSAID’s,   skin reacts., menstruat.disords., periph oed.
       meas.B.P.twice bef.commenc. ther. & monit.reg.dur.ther., appropr.an-  &gt; 35 kg: Adult dos.recomm.  Special precautions: Approv.for market.by MCC und.spec.restrict.
       tihypertens. ther. if need., pref.should be giv.to antihypertens. meds.   Contraindications: Pregn.& lactat.  distribut.programme (TRMP), pts. to be advis.& agree to comply
       that does not interf.with pharmacokinet.of ciclosporin e.g. isradi-  Side effects: Naus., diarrh., constipat., URTI, UTI, pain, periph.oed.,   with program. requirem., use 2 effect.simultan.contracept. meth-
       pine/nifedipine, elderly, biopsy of atypic.psosias.skin les.bef.com-  hypertens., anaem., headache, hyperkalaem., hypophosphataem.,   ods at least 4 wks.prior to admin./dur.ther.& and 4 weeks.follow.
                                     hypercholesterolaem., post-op.wound complicat., weight incr., incr.
       mencem., concom. methotrex., maint.ther.long.than 1 yr not recomm.   ther.discont., women who have not been menopaus.for at least 24
       in psorias., concom.drugs with nephrotox. synergy eg aminoglycos./  in bld.creatinine., hypersens./ anaphylact. reacts., capillar.leak syndr.,   consecut. mnths are consid.to be of child bear.potent., negat. pregn.
                                     cytokine release syndr., wheez., bronchosp., pulm.oed., card. fail.,
       amphotericin B/ ciprofloxac./ vancomycin/trimethoprim (+sulfameth-  test within 24 hrs.of begin.ther.where upon prescript.may be issued.,
       oxazole)/ NSAID’s/melphalan/H 2-recept. antagon.& methotrex., incr.  resp.fail., paeds.also: hypertrichos., rhinit., pyrex., viral infect., sepsis.  pres.in semen theref. latex condom use mandatory, pregn.test.wkly
                                     Warnings and special precautions: Do not admin. unless ab-
       nephrotox. potent. with concom.tacrolim., avoid high diet.K intake,   dur. 1  4 wks.rep.every 2-4 wks.thereaft.depend.on regular. of men-
                                                                     st
       avoid concom.nifedipine where gingiv. hyperplas. has develop.as   solut. cert.pt.to receiv.graft & concom. immunosuppress., adeq.  str.cycle, discont.immed.if pregn. suspect and refer to gynaecolog.
                                     contracept.in women of child-bear. potent.unt.4 mnths.aft.last dos.,
       S/E, observ.tox. manifestat. when admin.concurr.with digoxin/ col-  nd  exper.in reproduct. toxic., any suspect.foet.expos.to be immed. re-
       cich./ lovostatin/pravastat./simvastatin/ atorvastat./ fluvastatin, in   not to breastfeed for 4 mnths.foll. 2  dos.as pass.into breast milk.,   port.to MCC & Key Oncologics, pts./legal guard.if pt.betw.12&18 yrs.
                                     admin by exper.medic., re-expos.to subseq. course of ther., do not
       graft recipients revers. kidn. funct.impairm.with concom.fibric acid   to receiv.oral & writt. warn.of poss.hazards.& understand & agree
       derivat. report., freq.bld.lev./ren.funct.monitor.advis.when used in   mix with other meds/subst., giv. through separ.infus.line., cytokine   in writ. to all safety proced., potent.toxic.to breast feed childr., no
                                     release syndr. can caus.life-threat.pulm.oed esp.if pt.is fluid overload.
       transpl.pts.esp.dur.init./withdr.of concom. meds., pass.into breast   prescript.to cover more than 28 days, rep.prescript.where practit.not
       milk, monit.lipids & electrol., ser.Mg control recomm.in peri-transpl.   STELARA, Janssen Pharmaceutica [P/S] &  visit.prohibit., any suspect.advers.event observ.dur./within 8 wks. of
       per.with poss.supplementat., syndr.of thrombocytopaen./ thrombo-  Ustekinumab  stopp.treatm.to be report.immed, no bld./ semen to be donat.dur./
       embol.complic./ microangiopath. haemolyt.anaem.may result in   Indications: Mod.to sev.plaque psorias.in adults who are candidat.  within 8 wks.of stopp. ther., caps.not to be shar., pregn.to be excl.
       graph fail., psorias.& atop.dermat.pts.to avoid excess. unprotect.  for photother.or syst.ther.  bef.init. / extend.ther.in both adults & childr., modificat.in vir.load.
       sun expos.& ultraviol.B irradiat/ PUVA photochemother., allow active   (S4) INJ, 43/30.1/0727, 0728  of HIV infect.pts.with prolong.ther.theref.3 mnthly.monit.recomm.,
       H.simpl. infects. to clear/treat dermat.staphylocc.aureus infects. bef.  715819-001: 45 mg/0,5 ml, sngl.dos., R28 750,00  concom.meds.that may reduc. OC effectiven./known to cause neu-
       init.ther., monit.lymphadenopathy reg., poss. struct. chang develop.  723615-001: 90 mg/ml, sngl.dos., R28 750,00  ropathy, ren./hepat.dis., monit.for S&S of periph. neuropathy prior
       in kidn.dur.longt.ther.& must be different.from chron.reject.chang.  Dosage: Admin.by SC inj. Adults (18-64 yrs): Admin 45 mg at wk   to init.ther.& reg.thereaft.discont. ther.if confirm., neutrophil count
       Drug interactions: Fat rich meal or grapefruit juice incr.bioavaila-  0 & 4, then 12 wkly theraft. Pts.weigh.&gt;100 kg: Use 90 mg. 45 mg   to be &gt;750/mm  bef.init.ther. & discont.if counts falls bel.500/mm 3
                                                                         3
       bil., barbitur./carbamazepine/ oxcarbazepine/ phenytoin/nafcillin/  may also be giv.however 90 mg result.in great.effic. Admin. 8 wkly.  Drug interactions: Sedat.activ.of alcoh./other CNS depress./
       sulfadimidine/ IV trimethoprim/rifampicin/octreotide/probucol/   in pts.who do not respond adeq.to 12 wkly dos. Consid.discont.ther.  morph./neurolept./sedat H 1 antihistam./ centr.antihypertens.&
       orlistat,/St John’s wort/ticlopidine/sulfinpyrazone/ terbinafine   if no respons.up to 28 wks.  baclofen potent., incr.periph.neuropathy report.with zalcitabine/
       & bosentan decr.lev., macrolide antibiot./ ketoconazole/flucona-  Re-treatm: Dos.regim.of wks.0 & 4 aft.ther. interrupt. Elderly pts.   didanosine & stavudine.
       zole/itraconazole/ voriconazole/ diltiazem/nicardipine/verapamil/   ≥65 yrs: Same as adults.
       metoclopramide/OC’s/danazol/high dos. methylpredinisolone/   Contraindications: Concom.live vir./bact.vacc., safety & effic.in   TYSABRI, Litha [P/S] &
       allopurinol/amiodarone/ cholic acid & derivat./protease inhibits.  combin.with immunosuppress. agents/ photother.not est., lactat.,   Natalizumab
                                                                  Indications: Sngl.dis.modify.ther.in highly act. relaps. remitt.multip.
       eg sequinavir/ imatinib & colchicine incr.lev., AUC incr. with ler-  safety & effic.in childr. & adolesc.&lt; 18 yrs. not est., act.infects.incl. TB.
       canidipine, bioavailabil.of diclofenac. incr., clear.of digoxin/colchi-  Side effects: Nasopharyngit., URTI, herpes zoster,  cellulit., depress.,   scleros.in pts.with high dis. activ.despite beta-interferon treatm.or
       cine/HMG-CoA reduct. inhibit. & prednisolone reduc., everolimus/   dizzin., headache, pharyngolaryng. pain, back pain, nas.congest., di-  pts.with rapidly evolv. sev.relaps.remitt.multiple scleros. defin.by 2
       sirolimus bld.lev.incr.       arrh., prurit., myalg., fatig., loc.reacts.incl. erythema./indurat., hyper-  or more disabl.relaps.in one yr.& with 1 or more Gadolinium enhanc.
                                     sens.reacts., immunogenicity /antibody developm., ser.bact./ fung./  les.on brain MRI or signific.incr.in T2 les.load compar.to prev.rec.MRI.
       SIMPONI, Janssen [P/S] &      vir.infects., incr.infect.risk/latent infects. reactiv., cutan./noncutan.  (S4) CONC.FOR INFUS, 42/30.1/0765. 20 mg/ml
       Golimumab                     malign., diverticulit., osteomyelit., gastroenterit., pneumon., UTI.,   715826-001: 1x15 ml vial, R15 226,21
       Indications: In combin.with methotrex.for act. adult rheumat.arthrit.  exfol. dermatit., erythroderm.psorias.  Dosage: See product lit.for prep.& admin.techniq. Do not ad-
       where respons.to dis.-modify. anti-rheumat.drug (DMARD) ther.incl.  Warnings and special precautions: Concom. immunosuppress.   min.as bolus inj.
       MTX inadeq., act. adult rheum.arthrit.not prev.treat.with methotrex.,   agents, cons.benef./risk in pregn., no studies in ren.& hepat.impairm.,   Contin.& init.supervis.by exper.physic.in facilit. with access to MRI
       alone/in combinat.with methotrexate for act.adult psoriat.arthrit.  self-inj. und.physic. supervis., eval.for TB/treatm.for latent TB bef.init.  & where hypersens.reacts.can be manag. Admin.infus.aft.dilut.over
       where respons.to prev.DMARD ther.inadeq.,act.adult ankylos. spon-  ther., also in pts.with past hist.of latent/ act.TB in whom adeq.anti-  approx.1 hr. Observ. pt.dur.infus.& for 1 hr aft.complet. Admin. IV in-
       dylit. where respons.to convent. ther.inadeq.  TB treatm.cannot be confirm., monit.S&S of act.TB dur./aft.ther., incr.   fus.of 300 mg once every 4 wks. Cont.ther.to be caref.consid. in pts.
       (S4) SOL.FOR INJ, 43/30.1/0808. 50 mg/0,5 ml  malign. risk, chron.infect./infect.hist., alert physic. if S&S of infect.,   show.no therapeut. benef. beyond 6 mnths.
       719211-001: sngl.pre-fill.syr./pen, 1, R10 057,52  monit.pt.in case of ser. infect. & cont.ther.only aft.resolv., concom.  Contraindications: Progress.multifoc. leukoencephalopathy,
       Dosage: Admin.SC. Treatm.init.& supervis.by exper. med.practit.  inact./ non-live vacc. may be admin., discont.ther.& init. appropr.  pregn.& lactat., incr. opportunist. infect.risk incl.immunocompro-
       Rheumat. & psoriat.arthrit. & ankylos. spondylit: Adults   treatm.in case of anaphylact.reacts., malign. hist./contin.ther.in pts.  mis. pts., concom.beta-interferons or glatimer acetate, known act.
       18 yrs.& old: 50 mg once/ mnth. on same date each mnth.  develop.malign., monit. all pts.& particul.those &gt; 60 yrs.of age/pts.   malign.except.cutan.basal cell carcinoma, childr.& adolesc., pts.over
       Contraindications: Act.TB/other sev.infects., mod. to sev.HF (NYHA   with medic.hist.of prolong.immunosuppress.ther./ those with a hist.  65 yrs., safety & effic.of re-admin.not est., bolus inj. admin., safety &
       class III/IV), concom.live vaccin./ therapeut.infect.agents, lymphoma.,   of PUVA treatm.for appear.of non-melan.skin Ca, caution advis.when   effic.with other immunosuppress. & antineoplast.ther.not est., limit.
       act. CNS demyelat.pathol., pregn.& lactat.  admin.live vaccin.to household contacts of pts.because of potent.risk   exper.in treatm. durat.&gt; 3 yrs.
       Side effects: V.common: URTI, Common: Influenza, bronchit., cel-  for shedd.from the household contact and transmiss.to the pt., pts.  Side effects: Incr.PML risk usual.lead to sev. disabil. /death, CNS
       lulit., sinusit., oral herpes, dizzin., paraesthes., hypertens., pyrex., inj.  receiv./who have receiv.allergy immunother.partic.for anaphylax.  effs., headache, dizzin., GI disords., arthralg., UTI, nasopharyngit.,
       site reacts. Uncomm: Sept.shock/-arthrit./-bursit., sepsis, TB, LRTI,   See also MDR page 430.  pyrex., fatig., urticar., hypersens./skin reacts., hypotens., chest pain/
       pyelonephrit., abscess, clinic. sympt.exacerbat.&/ radiograph.evid.  discomf., hypertens., dyspn., angioed., infus.-relat.reacts.incl.rigor/
       of CNS demyelinat. disords.incl.MS & Guillan Barre, pustul. pso-  THALIDOMIDE CELGENE 50 mg, Key Oncologics [P/S]  N&V/flush., ser. hepat. events, incr.liv.enzym., hyperbilirubinaem.
       rias., decr.neutroph.count. Rare: Histoplasmos., coccidioidomycos.,   Thalidomide  Warnings and special precautions: Discont. ther. in pregn., pts.
       pneumocyt. jiroveci;(carinii) (PCP) infect.  Indications: Relaps./refract.multiple myeloma, ac.cutan.manifestat.  to be inform.of ther.risks & instruct. on early S&S of PML(progress.
       Warnings and special precautions: Concom. immunosuppress.  of mod.to sev.erythema nodosum leprosum (ENL)/ENL relaps.where   multifoc. leucoencephalopathy), re-inform aft.2 yrs.esp.incr. PML
       ther.& underly.condits.predispos. pts to infects., consid.risk vs. be-  thalidomide treatm.used bef., in combinat.with melphalan & pred-  risk, MRI bef.init.ther.& rep.yrly., monit.pt. reg. dur.ther.for new/
       nef.in pts.resid./ travel.to regions where invas.fung.infects.endem.,   nisone for the treatm.of pts.with untreat.multiple myeloma ≥ 65 yrs./  worsen.neurolog.S&S suggest. of PML, susp.ther.if PML suspect.
       chron.-/recurr.infect./hist.thereof, monit.for infects./risk fact. incl.TB   inelig.for high dos.chemother., in combinat.with dexamethasone for   until PML excl.& discont.ther.perm.if PML confirm., monit. pts.for
       bef./dur.& aft.treatm., TB risk fact.eval./test for latent TB bef.init.  the treatm.of pts. with untreat.multiple myeloma.  develpm.of immune reconstitut. inflamm. syndr.aft.treatm.withdr.,
       treatm., prophylact.anti-TB ther.with reduc.reactiv.risk, monit.for S&S   (S4) CAPS, 38/24/0258  opportunist. infects. risk, discont.ther.& init.appropr.treatm.at 1   st
       of act.TB dur./aft.treatm.incl.pts. who test.neg.for latent TB infect.,   709228-001: 50 mg, 28, R3 848,23  sympt.of hypersens.reacts., poss.incr.PML risk in pts.with treatm.
       malign.hist./pts. develop.malign. while on ther., more lymphoma   Dosage: Use is restrict.to pts/drs & pharmacists regis.in Phar-  hist.of immunosuppress.meds., confirm pt not immunocompromis.
       cases report.in pts.receiv.Simponi compar.to controls, more malign.re-  mion Risk Management Programme (PRMP). See manufact.lit.for   bef.start. treatm., immunogenicity antibody developm., poss. exac-
       port.in sev.persist.asthma pts., eval.HBV risk pts.bef.init.ther., ident.&   registrat.& prescrib. proced. Admin.at least 1 hr.aft.food. Dly.dos.  erbat. of abnorm.liv.funct., pts.to report S&S suggest.of liv.inj., Ty-
       monit. hepatit.B vir.(HBV) carriers dur.ther.& sev.mnths. aft.treatm.dis-  may be div.into 2 dos.  sabri remains in the bld.for approx.12 wks.follow.last dos.& addit.
       cont., monit.HF pts.closely & discont. ther.if new/worsen.HF sympt.  Untreat.Multiple myeloma: In combinat.with melphalan &   immunosuppress. eff.poss.with immunosuppress. meds. start.dur.
       appear, ser.infects. observ.with concom.anakinra, ther. does not sup-  prednisone: 200 mg/day. Max.12 cycl.of 6 wks. should be used.  this interv., prov.pt.with alert card, counsel.pt.on importance of un-
       press humoral immune respons.to pneumococc. polysaccharide vacc.,   In combinat.with dexamethasone: 200 mg per day.  interrupt.dos.esp. dur. early mnths.of treatm., inform medic. practit.</code></pre>
     	</div>
    
     </div>
     <div id="content-bottom">
       <div id="content-bottom2">
         <table width="110" border="0" cellspacing="0" cellpadding="0">
           <tr>
             <td width="22%" height="44"><a href="page365.html"><img src="images/previous.png" width="26" height="19" id="Image2" onmouseover="MM_swapImage('Image2','','images/previous2.png',1)" onmouseout="MM_swapImgRestore()" /></a></td>
             <td width="43%">
             	&nbsp;&nbsp;&nbsp;<a href="page361.html">361</a>&nbsp;&nbsp;&nbsp;<a href="page362.html">362</a>&nbsp;&nbsp;&nbsp;<a href="page363.html">363</a>&nbsp;&nbsp;&nbsp;<a href="page364.html">364</a>&nbsp;&nbsp;&nbsp;<a href="page365.html">365</a>&nbsp;&nbsp;&nbsp;<a href="page366.html">366</a>&nbsp;&nbsp;&nbsp;<a href="page367.html">367</a>&nbsp;&nbsp;&nbsp;<a href="page368.html">368</a>&nbsp;&nbsp;&nbsp;<a href="page369.html">369</a>&nbsp;&nbsp;&nbsp;<a href="page370.html">370</a>&nbsp;&nbsp;&nbsp;<a href="page371.html">371</a>
             </td>
             <td width="35%"><a href="page367.html"><img src="images/next.png" width="26" height="19" id="Image1" onmouseover="MM_swapImage('Image1','','images/next2.png',1)" onmouseout="MM_swapImgRestore()" /></a></td>
           </tr>
         </table>
       </div>
     </div>
  </div>
</div>
<div id="right-button">
  <p>&nbsp;</p>
  <p>&nbsp;</p>
  <p>&nbsp;</p>
  <p>&nbsp;</p>
  <p>&nbsp;</p>
  <p><a href="page367.html"><img src="images/next_big.png" width="90" height="80" /></a></p>
</div>


</div>

</body>
</html>
